[Lymphocyte transformation test following stimulation with a protein factor from neutrophilic granulocytes (PMNL) in psoriasis patients].
The lymphocyte transformation test (LTT) was given to 20 healthy subjects and 43 patients with generalized psoriasis vulgaris: it was given right after stimulation with PHA (spontaneous) and after stimulation with allogenic and autogenic protein factor (NPF). NPF was isolated from secondary lysosome granules of peripheral blood neutrophils. The results were analyzed using computer statistic tests. No distinct differences were noticed between the spontaneous transformation test in psoriatic patients compared to the controls. After stimulation with PHA, the percentage of blast cells was significantly lower in patients with psoriasis. When allogenic and autogenic NPF was used for stimulation, the LTT values were significantly higher in the psoriasis group than in the control subjects. This fact points out the increase in sensitivity of lymphocytes to NPF in active psoriasis and the possibility of abnormal neutrophil-lymphocyte interactions in vivo. This phenomenon may be intensified when under the influence of bacterial or viral agents, or medicaments; the degranulation of secondary lysosome granules of neutrophils occurs, causing the release of NPF. These investigations support our opinion that psoriasis is a systemic disease and that NPF plays a considerable role in the psoriatic reaction.
Ruszczak
Z
Z
Dermatologische Klinik, MMA Lódź.
Ciborska
L
L
Kaszuba
A
A
D000328:Adult; D000368:Aged; D023181:Antimicrobial Cationic Peptides; D001798:Blood Proteins / Q000276:immunology*; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology*; D011565:Psoriasis / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology
D023181:Antimicrobial Cationic Peptides; D001798:Blood Proteins; C030509:neutrophil basic proteins
Lymphozytentransformationstest nach Stimulation mit Proteinfaktor aus neutrophilen Granulozyten (PMNL) bei Psoriasiskranken.